Drug-induced disease

Many reports in the literature discuss aspects of drug-induced disease or injury which do not necessarily identify particular drugs or classes of drugs and their associated adverse drug reactions.

Such references might focus on the diagnosis, clinical pathology, pharmacology, pharmacogenomics or treatment of a drug-induced diseases or injury. Or analyse drug-induced diseases in relation to particular groups of the population (the young, the elderly, gender).

This area of the literature is accommodated in the Litt database under the category ‘Drug-induced disease (General)’ with further classification under the categories: skin; cardiovascular; central nervous system; endocrine/metabolic; gastrointestinal/hepatic etc. Litt’s weekly ‘Drug updates’ for subscribers lists ‘Drug-induced disease (General)’ as a separate heading with PubMed hyperlinks to references under these categories.

Drug-induced disease (Cardiovascular)

Drug-induced disease (Central Nervous System)

Drug-induced disease (Endocrine/Metabolic)

  • (2025): Ben Salem C+, Eur J Intern Med May, Online ahead of print (comment on Mannheimer B+, Eur J Intern Med, May 2025 (loc cit))
  • (2025): Borsari SF+, Praxis (Bern 1994) (German) 114(4), 149-153 [REVIEW] (adrenal insufficiency)
  • (2025): Mannheimer B+, Eur J Intern Med May, Online ahead of print [REVIEW]
  • (2025): Patel M+, Curr Atheroscler Rep 27(1), 52 [REVIEW]Pediatric
  • (2025): Song B+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2025): Song B+, BMC Pediatr 25(1), 515 [REVIEW]Pediatric (pharmacovigilance / pharmacoepidemiology)
  • (2025): Xi Y+, Andrology Sep, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2025): Xiao S+, Endocr Metab Immune Disord Drug Targets Aug, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2025): Yang H+, Front Pharmacol Apr (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2024): Ji X+, Expert Opin Drug Saf Sep, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
  • (2024): Yang X+, Clin Epidemiol 16, 617-630 (pharmacovigilance / pharmacoepidemiology)
  • (2012): Deepinder F+, Expert Opin Drug Saf 11(5), 779-95 [REVIEW]

Drug-induced disease (Gastrointestinal/Hepatic)

Drug-induced disease (Genitourinary)

  • (2025): Tian X+, Sci Rep 15(1), 15760 [REVIEW] (erectile dysfunction) (pharmacovigilance / pharmacoepidemiology)
  • (2025): Zheng G+, Sci Rep 15(1), 22856 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2024): Dai X+, Front Pharmacol Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2024): Li D+, Expert Opin Drug Saf Aug, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2024): Moodley D+, Int J Impot Res Dec, Online ahead of print [REVIEW]
  • (2024): Zheng F+, Expert Opin Drug Saf 23(11), 1419-1426, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
  • (2024): Zheng F+, Expert Opin Drug Saf Nov, Online ahead of print (pharmacovigilance / pharmacoepidemiology)

Drug-induced disease (Hair)

Drug-induced disease (Hematologic)

  • (2025): Wen X+, Int J Clin Pharm Jan, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2025): Xia K+, Cancer Control May (e-Collection) [REVIEW] (myelosuppression) (pharmacovigilance / pharmacoepidemiology)
  • (2024): Lu Y+, Front Pharmacol Dec (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2023): Mazzierli T+, Front Pharmacol Jan (e-Collection) [REVIEW]
  • (2019): Vo QT+, Ann Pharmacother 53(5), 523-536 [REVIEW] (Naranjo Adverse Drug Reaction Probability Scale)

Drug-induced disease (Mucosal)

Drug-induced disease (Nails)

Drug-induced disease (Neuromuscular/Skeletal)

Drug-induced disease (Ocular)

Drug-induced disease (Other)

  • (2025): Broe A+, Pharmacoepidemiol Drug Saf 34(9), e70211 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2025): Chen S+, Discov Oncol 16(1), 786 [REVIEW] (drug-induced second tumors) (pharmacovigilance / pharmacoepidemiology)
  • (2025): Mellou M+, Therapie Jul, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • Negative findings
  • (2024): Pivato CA+, Eur Heart J Dec, Online ahead of print [REVIEW] ("these findings suggest the cardiovascular safety of fertility treatments")
  • Negative findings
  • (2024): Zeng Y+, Andrology Oct, Online ahead of print (pharmacovigilance / pharmacoepidemiology)

Drug-induced disease (Otic)

  • (2025): Wu T+, Hear Res Apr, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
  • (2024): Li B+, Front Pharmacol Nov (e-Collection) (pharmacovigilance / pharmacoepidemiology)
  • (2021): Maia NPD+, Int Braz J Urol 47(4), 747-752 [REVIEW]

Drug-induced disease (Renal)

Drug-induced disease (Respiratory)

Drug-induced disease (Skin)